Stability-Indicating Hplc Method For Determination Of 7,8,9,10-Tetrahydroazepino[2,1b] Quinazolin-12(6h)-One, A Potential Anticancer Agent

7,8,9,10-tetrahydroazepino[2,1b] quinazolin-12(6H)-one, a synthetic analog of vasicine, has been reported to be an anticancer, bronchodilator, antiinflammatory, antitussive, antiarthritic and antiasthamatic compound, which is under preclinical development for anticancer activity. The development of a validated reverse phase high performance liquid chromatography method is herein reported for the analysis and stability assessment. The analytical method was optimized using a C18 column and methanol: water (80: 20 v/v) as mobile phase at flow rate of 0.9 ml/min. The eluents were monitored at 254 nm. Retention time of 7,8,9,10-tetrahydroazepino[2,1b] quinazolin-12(6H)-one was observed to be 3.9 min. It degraded significantly under alkaline conditions whereas negligible degradation was observed under acidic, oxidative, thermal and photolytic stress conditions. The peak of major degradation product, resulting from alkaline degradation, was well resolved from the peak of 7,8,9,10-tetrahydroazepino[2,1b] quinazolin-12(6H)-one. This method has been found to be linear, accurate, precise, robust, sensitive, specific, suitable and stability indicating.